Loading…
Reported covered position: See prior filing
How to read the money
Income and expense are whole-filing amounts associated with this lobbyist, not personal compensation or an allocated share.
No topic inference: each bill number appears in source LDA issue text assigned to this lobbyist.
Maintaining Investments in New Innovation Act
Client: NOVARTIS · Firm: BGR GOVERNMENT AFFAIRS
Provide strategic counsel and advocacy for issues related to policies impacting the pharmaceutical industry generally including drug shortages, patientout of pocket costs, supply chain, PBM policies, kidney care policies, Inflation Reduction Act (IRA) implementation issues, the Maintaining Investments in New Innovation (MINI) Act H.R.1672, tariffs, and biopharma innovation policies.
Maintaining Investments in New Innovation Act
Client: NOVARTIS · Firm: BGR GOVERNMENT AFFAIRS
Specific issues are shown only where the LDA source assigned them to this lobbyist. Targets apply to the associated filing.
ADVANCED MEDICAL TECHNOLOGY ASSOCIATION via BGR GOVERNMENT AFFAIRS
2025 · second_quarter · 2A
Provide guidance and strategic advice regarding regulation and coverage of medical devices, including diagnostic tests
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
ACADEMY OF NUTRITION AND DIETETICS via BGR GOVERNMENT AFFAIRS
2025 · first_quarter · 1A
Source: Senate LDA
| ELI LILLY & CO INC |
| 20 |
| 2013–2017 |
| FRESENIUS MEDICAL CARE | 20 | 2013–2017 |
| GILEAD SCIENCES, INC. | 20 | 2013–2017 |
| GENENTECH INC | 17 | 2014–2017 |
| ADVANCED MEDICAL TECHNOLOGY ASSOCIATION | 13 | 2016–2025 |
| CELGENE CORPORATION | 13 | 2015–2017 |
| MERCK & CO., INC. | 13 | 2015–2017 |
| SANOFI US SERVICES INC | 13 | 2015–2017 |
| SENIOR CARE PHARMACY COALITION | 13 | 2015–2017 |
| NUCLEAR ENERGY INSTITUTE | 10 | 2015–2017 |
| WORKING GROUP FOR PHARMACEUTICAL SAFETY | 10 | 2013–2015 |
| PFIZER, INC. | 9 | 2016–2017 |
| RAI SERVICES COMPANY | 9 | 2017–2025 |
| EGALET CORPORATION | 8 | 2016–2017 |
| EXPEDIA, INC. | 8 | 2013–2015 |
| PERNIX THERAPEUTICS | 8 | 2015–2016 |
| A PLACE FOR MOM, INC. | 7 | 2024–2025 |
| AMERICAN HEALTH CARE ASSOCIATION | 7 | 2023–2025 |
| Alnylam Pharmaceuticals, Inc. | 7 | 2016–2017 |
| CHELSEA THERAPEUTICS | 7 | 2013–2014 |
| DEA SCHEDULING COALITION (INFORMAL COALITION) | 7 | 2014–2015 |
| BIOTECHNOLOGY INNOVATION ORGANIZATION | 6 | 2023–2025 |
| EVERYONE MEDICINES | 6 | 2024–2025 |
| GLAXOSMITHKLINE, INC. | 6 | 2013–2014 |
| GRAIL, LLC | 6 | 2023–2024 |
| JOHNSON & JOHNSON | 6 | 2016 |
| NOVARTIS | 6 | 2024–2025 |
| ACADEMY OF NUTRITION & DIETETICS | 5 | 2024–2025 |
| BIOMERIEUX, INC. | 5 | 2024–2025 |
| BREAKTHROUGH T1D (F/K/A JDRF) | 5 | 2024–2025 |
| LOCKTON MANAGEMENT, LLC | 5 | 2017 |
| PHARMA & BIOPHARMA OUTSOURCING ASSOCIATION | 5 | 2017 |
| ShiftKey, LLC | 5 | 2024–2025 |
| ALLERGAN, INC. | 4 | 2014 |
| APPLIED BIOLOGICS | 4 | 2024–2025 |
| CUISINE SOLUTIONS, INC. | 4 | 2024–2025 |
| HUNTINGTON INGALLS INDUSTRIES, INC. (FKA HUNTINGTON INGALLS INCORPORATED) | 4 | 2016 |
| MILLENNIUM: THE TAKEDA ONCOLOGY COMPANY | 4 | 2013 |
| AMEDISYS, INC. | 3 | 2017 |
| EPIGENOMICS INC. | 3 | 2017 |
| FLEXION THERAPEUTICS, INC. | 3 | 2017 |
| PTC THERAPEUTICS | 3 | 2024–2025 |
| ROIVANT SCIENCES, INC. | 3 | 2017 |
| Vaxcyte, Inc. | 3 | 2024–2025 |
| CENTENE CORPORATION | 2 | 2017 |
| NEUROCRINE BIOSCIENCES, INC | 2 | 2017 |
Provide strategic counsel and advocacy for issues related to policies impacting the pharmaceutical industry generally including drug shortages, patientout of pocket costs, supply chain, PBM policies, kidney care policies, Inflation Reduction Act (IRA) implementation issues, the Maintaining Investments in New Innovation (MINI) Act H.R.1672, tariffs, and biopharma innovation policies.
Maintaining Investments in New Innovation Act
Client: NOVARTIS · Firm: BGR GOVERNMENT AFFAIRS
Provide strategic counsel and advocacy for issues related to policies impacting the pharmaceutical industry generally including drug shortages, patient out of pocket costs, supply chain, PBM policies, kidney care policies, Inflation Reduction Act (IRA) implementation issues, the Maintaining Investments in New Innovation (MINI) Act S. 476/H.R.5547, and biopharma innovation policies.
Maintaining Investments in New Innovation Act
Client: NOVARTIS · Firm: BGR GOVERNMENT AFFAIRS
Provide strategic counsel and advocacy for issues related to policies impacting the pharmaceutical industry generally including drug shortages, patient out of pocket costs, supply chain, PBM policies, kidney care policies, Inflation Reduction Act (IRA) implementation issues, the Maintaining Investments in New Innovation (MINI) Act S. 476/H.R.5547, and biopharma innovation policies.
Maintaining Investments in New Innovation Act
Client: NOVARTIS · Firm: BGR GOVERNMENT AFFAIRS
Provide strategic counsel and advocacy for issues related to policies impacting the pharmaceutical industry generally including drug shortages, patient out of pocket costs, supply chain, PBM policies, kidney care policies, Inflation Reduction Act (IRA) implementation issues, the Maintaining Investments in New Innovation (MINI) Act S. 476/H.R.5547, and biopharma innovation policies.
Maintaining Investments in New Innovation Act
Client: NOVARTIS · Firm: BGR GOVERNMENT AFFAIRS
Provide strategic counsel and advocacy for issues related to policies impacting the pharmaceutical industry generally including drug shortages, patient out of pocket costs, supply chain, PBM policies, kidney care policies, Inflation Reduction Act (IRA) implementation issues, the Maintaining Investments in New Innovation (MINI) Act S. 476/H.R.5547, and biopharma innovation policies.
Maintaining Investments in New Innovation Act
Client: NOVARTIS · Firm: BGR GOVERNMENT AFFAIRS
Provide strategic counsel and advocacy for issues related to policies impacting the pharmaceutical industry generally including drug shortages, patient out of pocket costs, supply chain, PBM policies, kidney care policies, Inflation Reduction Act (IRA) implementation issues, the Maintaining Investments in New Innovation (MINI) Act S. 476/H.R.5547, biopharma innovation policies and Rare Pediatric Disease Priority Review Voucher program policies.
Maintaining Investments in New Innovation Act
Client: NOVARTIS · Firm: BGR GOVERNMENT AFFAIRS
Provide strategic counsel and advocacy for issues related to policies impacting the pharmaceutical industry generally including drug shortages, patient out of pocket costs, supply chain, PBM policies, kidney care policies, Inflation Reduction Act (IRA) implementation issues, the Maintaining Investments in New Innovation (MINI) Act S. 476/H.R.5547, and biopharma innovation policies.
Provide strategic counsel and advocacy for issues related to policies impacting the pharmaceutical industry generally including drug shortages, patient out of pocket costs, supply chain, PBM policies, kidney care policies, Inflation Reduction Act (IRA) implementation issues, the Maintaining Investments in New Innovation (MINI) Act S. 476/H.R.5547, and biopharma innovation policies.
Provide strategic counsel and advocacy for issues related to policies impacting the pharmaceutical industry generally including drug shortages, patient out of pocket costs, supply chain, PBM policies, kidney care policies, Inflation Reduction Act (IRA) implementation issues, the Maintaining Investments in New Innovation (MINI) Act S. 476/H.R.5547, and biopharma innovation policies.
Provide strategic counsel and advocacy for issues related to policies impacting the pharmaceutical industry generally including drug shortages, patient out of pocket costs, supply chain, PBM policies, kidney care policies, Inflation Reduction Act (IRA) implementation issues, the Maintaining Investments in New Innovation (MINI) Act S. 476/H.R.5547, biopharma innovation policies and Rare Pediatric Disease Priority Review Voucher program policies.
Provide strategic counsel and advocacy for issues related to policies impacting the pharmaceutical industry generally including drug shortages, patient out of pocket costs, supply chain, PBM policies, kidney care policies, Inflation Reduction Act (IRA) implementation issues, the Maintaining Investments in New Innovation (MINI) Act S. 476/H.R.5547, and biopharma innovation policies.
Provide strategic counsel and advocacy for issues related to policies impacting the pharmaceutical industry generally including drug shortages, patient out of pocket costs, supply chain, PBM policies, kidney care policies, Inflation Reduction Act (IRA) implementation issues, the Maintaining Investments in New Innovation (MINI) Act S. 476/H.R.5547, and biopharma innovation policies.
Provide strategic counsel and advocacy for issues related to policies impacting the pharmaceutical industry generally including drug shortages, patient out of pocket costs, supply chain, PBM policies, kidney care policies, Inflation Reduction Act (IRA) implementation issues, the Maintaining Investments in New Innovation (MINI) Act S. 476/H.R.5547, and biopharma innovation policies.
Improving Transparency and Accuracy in Medicare Part D Spending Act
Client: SENIOR CARE PHARMACY COALITION · Firm: BGR GOVERNMENT AFFAIRS
Legislation and regulations affecting the long-term care pharmacy industry, S413, HR1316, HR1038
Improving Transparency and Accuracy in Medicare Part D Spending Act
Client: SENIOR CARE PHARMACY COALITION · Firm: BGR GOVERNMENT AFFAIRS
Legislation and regulations affecting the long-term care pharmacy industry, S413, HR1316, HR1038
Improving Transparency and Accuracy in Medicare Part D Spending Act
Client: SENIOR CARE PHARMACY COALITION · Firm: BGR GOVERNMENT AFFAIRS
Legislation and regulations affecting the long-term care pharmacy industry, S413, HR1316, HR1038
Prescription Drug Price Transparency Act
Client: SENIOR CARE PHARMACY COALITION · Firm: BGR GOVERNMENT AFFAIRS
Legislation and regulations affecting the long-term care pharmacy industry, S413, HR1316, HR1038
Prescription Drug Price Transparency Act
Client: SENIOR CARE PHARMACY COALITION · Firm: BGR GOVERNMENT AFFAIRS
Legislation and regulations affecting the long-term care pharmacy industry, S413, HR1316, HR1038
Prescription Drug Price Transparency Act
Client: SENIOR CARE PHARMACY COALITION · Firm: BGR GOVERNMENT AFFAIRS
Legislation and regulations affecting the long-term care pharmacy industry, S413, HR1316, HR1038
Improving Transparency and Accuracy in Medicare Part D Spending Act
Client: SENIOR CARE PHARMACY COALITION · Firm: BGR GOVERNMENT AFFAIRS
Legislation and regulations affecting the long-term care pharmacy industry, S413, HR1316, HR1038
Improving Transparency and Accuracy in Medicare Part D Spending Act
Client: SENIOR CARE PHARMACY COALITION · Firm: BGR GOVERNMENT AFFAIRS
Legislation and regulations affecting the long-term care pharmacy industry, S413, HR1316, HR1038
Improving Transparency and Accuracy in Medicare Part D Spending Act
Client: SENIOR CARE PHARMACY COALITION · Firm: BGR GOVERNMENT AFFAIRS
Legislation and regulations affecting the long-term care pharmacy industry, S413, HR1316, HR1038
Ariel Grace's Law
Client: ADVANCED MEDICAL TECHNOLOGY ASSOCIATION · Firm: BGR GOVERNMENT AFFAIRS
H.R. 6 21st Century Cures Act Innovation for Healthier Americans House and Senate Agriculture Appropriations bills S. 1077, The Advancing Breakthrough Medical Devices for Patients Act of 2015 S.1622, FDA Device Accountability Act of 2015 S.2737, Improving Medical Device Innovation Act Issues related to lab developed tests H.R. 5403, To amend the Federal Food, Drug, and Cosmetic Act with respect to liability under State and local requirements respecting devices. proposals related to Medicare Parts A & B
Ariel Grace's Law
Client: ADVANCED MEDICAL TECHNOLOGY ASSOCIATION · Firm: BGR GOVERNMENT AFFAIRS
H.R. 6 21st Century Cures Act Innovation for Healthier Americans House and Senate Agriculture Appropriations bills S. 1077, The Advancing Breakthrough Medical Devices for Patients Act of 2015 S.1622, FDA Device Accountability Act of 2015 S.2737, Improving Medical Device Innovation Act Issues related to lab developed tests H.R. 5403, To amend the Federal Food, Drug, and Cosmetic Act with respect to liability under State and local requirements respecting devices. proposals related to Medicare Parts A & B
Ariel Grace's Law
Client: ADVANCED MEDICAL TECHNOLOGY ASSOCIATION · Firm: BGR GOVERNMENT AFFAIRS
H.R. 6 21st Century Cures Act Innovation for Healthier Americans House and Senate Agriculture Appropriations bills S. 1077, The Advancing Breakthrough Medical Devices for Patients Act of 2015 S.1622, FDA Device Accountability Act of 2015 S.2737, Improving Medical Device Innovation Act Issues related to lab developed tests H.R. 5403, To amend the Federal Food, Drug, and Cosmetic Act with respect to liability under State and local requirements respecting devices. proposals related to Medicare Parts A & B
Ariel Grace's Law
Client: ADVANCED MEDICAL TECHNOLOGY ASSOCIATION · Firm: BGR GOVERNMENT AFFAIRS
H.R. 6 21st Century Cures Act Innovation for Healthier Americans House and Senate Agriculture Appropriations bills S. 1077, The Advancing Breakthrough Medical Devices for Patients Act of 2015 S.1622, FDA Device Accountability Act of 2015 S.2737, Improving Medical Device Innovation Act Issues related to lab developed tests H.R. 5403, To amend the Federal Food, Drug, and Cosmetic Act with respect to liability under State and local requirements respecting devices. proposals related to Medicare Parts A & B
Issues affecting the senior care pharmacy industry; H.R.6
21st Century Cures Act
Client: ADVANCED MEDICAL TECHNOLOGY ASSOCIATION · Firm: BGR GOVERNMENT AFFAIRS
H.R. 6 21st Century Cures Act Innovation for Healthier Americans House and Senate Agriculture Appropriations bills S. 1077, The Advancing Breakthrough Medical Devices for Patients Act of 2015 S.1622, FDA Device Accountability Act of 2015 S.2737, Improving Medical Device Innovation Act Issues related to lab developed tests H.R. 5403, To amend the Federal Food, Drug, and Cosmetic Act with respect to liability under State and local requirements respecting devices. proposals related to Medicare Parts A & B
Issues affecting the senior care pharmacy industry; H.R.6
21st Century Cures Act
Client: ADVANCED MEDICAL TECHNOLOGY ASSOCIATION · Firm: BGR GOVERNMENT AFFAIRS
H.R. 6 21st Century Cures Act Innovation for Healthier Americans House and Senate Agriculture Appropriations bills S. 1077, The Advancing Breakthrough Medical Devices for Patients Act of 2015 S.1622, FDA Device Accountability Act of 2015 S.2737, Improving Medical Device Innovation Act Issues related to lab developed tests H.R. 5403, To amend the Federal Food, Drug, and Cosmetic Act with respect to liability under State and local requirements respecting devices. proposals related to Medicare Parts A & B
Issues affecting the senior care pharmacy industry; H.R.6
Issues affecting the senior care pharmacy industry; H.R.6
21st Century Cures Act
Client: ADVANCED MEDICAL TECHNOLOGY ASSOCIATION · Firm: BGR GOVERNMENT AFFAIRS
H.R. 6 21st Century Cures Act Innovation for Healthier Americans House and Senate Agriculture Appropriations bills S. 1077, The Advancing Breakthrough Medical Devices for Patients Act of 2015 S.1622, FDA Device Accountability Act of 2015 S.2737, Improving Medical Device Innovation Act Issues related to lab developed tests H.R. 5403, To amend the Federal Food, Drug, and Cosmetic Act with respect to liability under State and local requirements respecting devices. proposals related to Medicare Parts A & B
21st Century Cures Act
Client: ADVANCED MEDICAL TECHNOLOGY ASSOCIATION · Firm: BGR GOVERNMENT AFFAIRS
H.R. 6 21st Century Cures Act Innovation for Healthier Americans House and Senate Agriculture Appropriations bills S. 1077, The Advancing Breakthrough Medical Devices for Patients Act of 2015 S.1622, FDA Device Accountability Act of 2015 S.2737, Improving Medical Device Innovation Act Issues related to lab developed tests H.R. 5403, To amend the Federal Food, Drug, and Cosmetic Act with respect to liability under State and local requirements respecting devices. proposals related to Medicare Parts A & B
Advancing Breakthrough Devices for Patients Act of 2016
Client: ADVANCED MEDICAL TECHNOLOGY ASSOCIATION · Firm: BGR GOVERNMENT AFFAIRS
H.R. 6 21st Century Cures Act Innovation for Healthier Americans House and Senate Agriculture Appropriations bills S. 1077, The Advancing Breakthrough Medical Devices for Patients Act of 2015 S.1622, FDA Device Accountability Act of 2015 S.2737, Improving Medical Device Innovation Act Issues related to lab developed tests H.R. 5403, To amend the Federal Food, Drug, and Cosmetic Act with respect to liability under State and local requirements respecting devices. proposals related to Medicare Parts A & B
Advancing Breakthrough Devices for Patients Act of 2016
Client: ADVANCED MEDICAL TECHNOLOGY ASSOCIATION · Firm: BGR GOVERNMENT AFFAIRS
H.R. 6 21st Century Cures Act Innovation for Healthier Americans House and Senate Agriculture Appropriations bills S. 1077, The Advancing Breakthrough Medical Devices for Patients Act of 2015 S.1622, FDA Device Accountability Act of 2015 S.2737, Improving Medical Device Innovation Act Issues related to lab developed tests H.R. 5403, To amend the Federal Food, Drug, and Cosmetic Act with respect to liability under State and local requirements respecting devices. proposals related to Medicare Parts A & B
Advancing Breakthrough Devices for Patients Act of 2016
Client: ADVANCED MEDICAL TECHNOLOGY ASSOCIATION · Firm: BGR GOVERNMENT AFFAIRS
H.R. 6 21st Century Cures Act Innovation for Healthier Americans House and Senate Agriculture Appropriations bills S. 1077, The Advancing Breakthrough Medical Devices for Patients Act of 2015 S.1622, FDA Device Accountability Act of 2015 S.2737, Improving Medical Device Innovation Act Issues related to lab developed tests H.R. 5403, To amend the Federal Food, Drug, and Cosmetic Act with respect to liability under State and local requirements respecting devices. proposals related to Medicare Parts A & B
Advancing Breakthrough Devices for Patients Act of 2016
Client: ADVANCED MEDICAL TECHNOLOGY ASSOCIATION · Firm: BGR GOVERNMENT AFFAIRS
H.R. 6 21st Century Cures Act Innovation for Healthier Americans House and Senate Agriculture Appropriations bills S. 1077, The Advancing Breakthrough Medical Devices for Patients Act of 2015 S.1622, FDA Device Accountability Act of 2015 S.2737, Improving Medical Device Innovation Act Issues related to lab developed tests H.R. 5403, To amend the Federal Food, Drug, and Cosmetic Act with respect to liability under State and local requirements respecting devices. proposals related to Medicare Parts A & B
FDA Device Accountability Act of 2016
Client: ADVANCED MEDICAL TECHNOLOGY ASSOCIATION · Firm: BGR GOVERNMENT AFFAIRS
H.R. 6 21st Century Cures Act Innovation for Healthier Americans House and Senate Agriculture Appropriations bills S. 1077, The Advancing Breakthrough Medical Devices for Patients Act of 2015 S.1622, FDA Device Accountability Act of 2015 S.2737, Improving Medical Device Innovation Act Issues related to lab developed tests H.R. 5403, To amend the Federal Food, Drug, and Cosmetic Act with respect to liability under State and local requirements respecting devices. proposals related to Medicare Parts A & B
FDA Device Accountability Act of 2016
Client: ADVANCED MEDICAL TECHNOLOGY ASSOCIATION · Firm: BGR GOVERNMENT AFFAIRS
H.R. 6 21st Century Cures Act Innovation for Healthier Americans House and Senate Agriculture Appropriations bills S. 1077, The Advancing Breakthrough Medical Devices for Patients Act of 2015 S.1622, FDA Device Accountability Act of 2015 S.2737, Improving Medical Device Innovation Act Issues related to lab developed tests H.R. 5403, To amend the Federal Food, Drug, and Cosmetic Act with respect to liability under State and local requirements respecting devices. proposals related to Medicare Parts A & B
FDA Device Accountability Act of 2016
Client: ADVANCED MEDICAL TECHNOLOGY ASSOCIATION · Firm: BGR GOVERNMENT AFFAIRS
H.R. 6 21st Century Cures Act Innovation for Healthier Americans House and Senate Agriculture Appropriations bills S. 1077, The Advancing Breakthrough Medical Devices for Patients Act of 2015 S.1622, FDA Device Accountability Act of 2015 S.2737, Improving Medical Device Innovation Act Issues related to lab developed tests H.R. 5403, To amend the Federal Food, Drug, and Cosmetic Act with respect to liability under State and local requirements respecting devices. proposals related to Medicare Parts A & B
FDA Device Accountability Act of 2016
Client: ADVANCED MEDICAL TECHNOLOGY ASSOCIATION · Firm: BGR GOVERNMENT AFFAIRS
H.R. 6 21st Century Cures Act Innovation for Healthier Americans House and Senate Agriculture Appropriations bills S. 1077, The Advancing Breakthrough Medical Devices for Patients Act of 2015 S.1622, FDA Device Accountability Act of 2015 S.2737, Improving Medical Device Innovation Act Issues related to lab developed tests H.R. 5403, To amend the Federal Food, Drug, and Cosmetic Act with respect to liability under State and local requirements respecting devices. proposals related to Medicare Parts A & B
Improving Medical Device Innovation Act
Client: ADVANCED MEDICAL TECHNOLOGY ASSOCIATION · Firm: BGR GOVERNMENT AFFAIRS
H.R. 6 21st Century Cures Act Innovation for Healthier Americans House and Senate Agriculture Appropriations bills S. 1077, The Advancing Breakthrough Medical Devices for Patients Act of 2015 S.1622, FDA Device Accountability Act of 2015 S.2737, Improving Medical Device Innovation Act Issues related to lab developed tests H.R. 5403, To amend the Federal Food, Drug, and Cosmetic Act with respect to liability under State and local requirements respecting devices. proposals related to Medicare Parts A & B
Improving Medical Device Innovation Act
Client: ADVANCED MEDICAL TECHNOLOGY ASSOCIATION · Firm: BGR GOVERNMENT AFFAIRS
H.R. 6 21st Century Cures Act Innovation for Healthier Americans House and Senate Agriculture Appropriations bills S. 1077, The Advancing Breakthrough Medical Devices for Patients Act of 2015 S.1622, FDA Device Accountability Act of 2015 S.2737, Improving Medical Device Innovation Act Issues related to lab developed tests H.R. 5403, To amend the Federal Food, Drug, and Cosmetic Act with respect to liability under State and local requirements respecting devices. proposals related to Medicare Parts A & B
Improving Medical Device Innovation Act
Client: ADVANCED MEDICAL TECHNOLOGY ASSOCIATION · Firm: BGR GOVERNMENT AFFAIRS
H.R. 6 21st Century Cures Act Innovation for Healthier Americans House and Senate Agriculture Appropriations bills S. 1077, The Advancing Breakthrough Medical Devices for Patients Act of 2015 S.1622, FDA Device Accountability Act of 2015 S.2737, Improving Medical Device Innovation Act Issues related to lab developed tests H.R. 5403, To amend the Federal Food, Drug, and Cosmetic Act with respect to liability under State and local requirements respecting devices. proposals related to Medicare Parts A & B
Improving Medical Device Innovation Act
Client: ADVANCED MEDICAL TECHNOLOGY ASSOCIATION · Firm: BGR GOVERNMENT AFFAIRS
H.R. 6 21st Century Cures Act Innovation for Healthier Americans House and Senate Agriculture Appropriations bills S. 1077, The Advancing Breakthrough Medical Devices for Patients Act of 2015 S.1622, FDA Device Accountability Act of 2015 S.2737, Improving Medical Device Innovation Act Issues related to lab developed tests H.R. 5403, To amend the Federal Food, Drug, and Cosmetic Act with respect to liability under State and local requirements respecting devices. proposals related to Medicare Parts A & B
Issues affecting the senior care pharmacy industry; H.R.6
Issues affecting the senior care pharmacy industry; H.R.6
Provide strategic counsel and advocate on issues related to health care coverage for Medical Nutritional Therapy and Intensive behavior health and other priorities for the Academy of Nutrition and Dietetics
Filing targets: Centers For Medicare and Medicaid Services (CMS), HOUSE OF REPRESENTATIVES, SENATE
CUISINE SOLUTIONS, INC. via BGR GOVERNMENT AFFAIRS
2025 · first_quarter · Q1
Provide strategic counsel and advocate on issues related to importing and exporting of sous vide products
Provide strategic counsel and advocate on issues related to importing and exporting of sous vide products
Filing targets: Agriculture, Dept of (USDA), SENATE
A PLACE FOR MOM, INC. via BGR GOVERNMENT AFFAIRS
2025 · first_quarter · 1A
Provide strategic guidance and advocacy regarding Congressional oversight of the Senior Living Referral sector.
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
BREAKTHROUGH T1D (F/K/A JDRF) via BGR GOVERNMENT AFFAIRS
2025 · first_quarter · Q1
Provide strategic counsel and advocate on issues related to Type 1 Diabetes policy
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
BIOMERIEUX, INC. via BGR GOVERNMENT AFFAIRS
2025 · first_quarter · 1A
Provide strategic counsel and advocate on issues related to diagnostic testing issues generally and bioMerieux specifically.
Filing targets: Centers For Medicare and Medicaid Services (CMS), HOUSE OF REPRESENTATIVES, SENATE
APPLIED BIOLOGICS via BGR GOVERNMENT AFFAIRS
2025 · first_quarter · 1A
Advocate on issues related to Medicare coverage
Filing targets: Centers For Medicare and Medicaid Services (CMS), HOUSE OF REPRESENTATIVES, SENATE
VAXCYTE, INC. via BGR GOVERNMENT AFFAIRS
2025 · first_quarter · Q1
Provide strategic counsel and advocate on issues related to vaccine development
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
EVERYONE MEDICINES via BGR GOVERNMENT AFFAIRS
2025 · first_quarter · Q1
Provide strategic counsel and advocate on issues related to rare disease drug development
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
SHIFTKEY, LLC via BGR GOVERNMENT AFFAIRS
2025 · first_quarter · Q1
Provide strategic counsel and advocate on issues related to healthcare workforce and technology and independent contractor classification
Filing targets: Federal Trade Commission (FTC), HOUSE OF REPRESENTATIVES, SENATE
NOVARTIS via BGR GOVERNMENT AFFAIRS
2025 · first_quarter · Q1
Provide strategic counsel and advocacy for issues related to policies impacting the pharmaceutical industry generally including drug shortages, patientout of pocket costs, supply chain, PBM policies, kidney care policies, Inflation Reduction Act (IRA) implementation issues, the Maintaining Investments in New Innovation (MINI) Act H.R.1672, tariffs, and biopharma innovation policies.
Provide strategic counsel and advocacy for issues related to policies impacting the pharmaceutical industry generally including drug shortages, patientout of pocket costs, supply chain, PBM policies, kidney care policies, Inflation Reduction Act (IRA) implementation issues, the Maintaining Investments in New Innovation (MINI) Act H.R.1672, tariffs, and biopharma innovation policies.
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
PTC THERAPEUTICS via BGR GOVERNMENT AFFAIRS
2025 · first_quarter · Q1
Provide guidance and advocacy with regard to regulations and legislation that could impact the pharmaceutical industry generally, and PTC specifically.
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
BIOTECHNOLOGY INNOVATION ORGANIZATION via BGR GOVERNMENT AFFAIRS
2025 · first_quarter · Q1
Advise and advocate on client's behalf regarding ongoing public policy concerns impacting the innovative biotechnology industry in Congress and throughout the Administration
Filing targets: Centers For Medicare and Medicaid Services (CMS), HOUSE OF REPRESENTATIVES, SENATE
RAI SERVICES COMPANY via BGR GOVERNMENT AFFAIRS
2025 · first_quarter · Q1
Provide monitoring, analysis, advise and support services related to legislative and administrative policies impacting the tobacco industry
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
ADVANCED MEDICAL TECHNOLOGY ASSOCIATION via BGR GOVERNMENT AFFAIRS
2025 · first_quarter · 1A
Provide guidance and strategic advice regarding regulation and coverage of medical devices, including diagnostic tests
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
AMERICAN HEALTH CARE ASSOCIATION via BGR GOVERNMENT AFFAIRS
2025 · first_quarter · 1A
Long-term care reform; Medicare and Medicaid payment policy; Medicare Advantage policy; arbitration issues; implementation of health care reform; bad debt relief; SGR replacement; NOTICE Act; Nurse staffing shortage; appropriations
Filing targets: Centers For Medicare and Medicaid Services (CMS), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), SENATE
ALKERMES, INC. via BGR GOVERNMENT AFFAIRS
2025 · first_quarter · 1A
Provide strategic counsel and advocate on issues related to the biopharmaceutical industry generally, and Alkermes, Inc. specifically
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
PHARMACEUTICAL RESEARCH AND MANUFACTURERS OF AMERICA via BGR GOVERNMENT AFFAIRS
2025 · first_quarter · Q1
Advise and advocate on clients behalf regarding ongoing public policy concerns impacting the innovative biopharmaceutical industry in Congress and throughout the Administration.
Filing targets: Centers For Medicare and Medicaid Services (CMS), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), SENATE
BIOMERIEUX, INC. via BGR GOVERNMENT AFFAIRS
2025 · first_quarter · Q1
Provide strategic counsel and advocate on issues related to diagnostic testing issues generally and bioMerieux specifically.
Filing targets: Centers For Medicare and Medicaid Services (CMS), HOUSE OF REPRESENTATIVES, SENATE
APPLIED BIOLOGICS via BGR GOVERNMENT AFFAIRS
2025 · first_quarter · Q1
Advocate on issues related to Medicare coverage
Filing targets: Centers For Medicare and Medicaid Services (CMS), HOUSE OF REPRESENTATIVES, SENATE
AMERICAN HEALTH CARE ASSOCIATION via BGR GOVERNMENT AFFAIRS
2025 · first_quarter · Q1
Long-term care reform; Medicare and Medicaid payment policy; Medicare Advantage policy; arbitration issues; implementation of health care reform; bad debt relief; SGR replacement; NOTICE Act; Nurse staffing shortage; appropriations
Filing targets: Centers For Medicare and Medicaid Services (CMS), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), SENATE
ALKERMES, INC. via BGR GOVERNMENT AFFAIRS
2025 · first_quarter · Q1
Provide strategic counsel and advocate on issues related to the biopharmaceutical industry generally, and Alkermes, Inc. specifically
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
ADVANCED MEDICAL TECHNOLOGY ASSOCIATION via BGR GOVERNMENT AFFAIRS
2025 · first_quarter · Q1
Provide guidance and strategic advice regarding regulation and coverage of medical devices, including diagnostic tests
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
ACADEMY OF NUTRITION AND DIETETICS via BGR GOVERNMENT AFFAIRS
2025 · first_quarter · Q1
Provide strategic counsel and advocate on issues related to health care coverage for Medical Nutritional Therapy and Intensive behavior health and other priorities for the Academy of Nutrition and Dietetics
Filing targets: Centers For Medicare and Medicaid Services (CMS), HOUSE OF REPRESENTATIVES, SENATE
A PLACE FOR MOM, INC. via BGR GOVERNMENT AFFAIRS
2025 · first_quarter · Q1
Provide strategic guidance and advocacy regarding Congressional oversight of the Senior Living Referral sector.
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
NOVARTIS via BGR GOVERNMENT AFFAIRS
2024 · fourth_quarter · 4A
Provide strategic counsel and advocacy for issues related to policies impacting the pharmaceutical industry generally including drug shortages, patient out of pocket costs, supply chain, PBM policies, kidney care policies, Inflation Reduction Act (IRA) implementation issues, the Maintaining Investments in New Innovation (MINI) Act S. 476/H.R.5547, and biopharma innovation policies.
Provide strategic counsel and advocacy for issues related to policies impacting the pharmaceutical industry generally including drug shortages, patient out of pocket costs, supply chain, PBM policies, kidney care policies, Inflation Reduction Act (IRA) implementation issues, the Maintaining Investments in New Innovation (MINI) Act S. 476/H.R.5547, biopharma innovation policies and Rare Pediatric Disease Priority Review Voucher program policies.
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
APPLIED BIOLOGICS via BGR GOVERNMENT AFFAIRS
2024 · fourth_quarter · Q4
Advocate on issues related to Medicare coverage
Filing targets: Centers For Medicare and Medicaid Services (CMS), HOUSE OF REPRESENTATIVES, SENATE
VAXCYTE, INC. via BGR GOVERNMENT AFFAIRS
2024 · fourth_quarter · Q4
Provide strategic counsel and advocate on issues related to vaccine development
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
ACADEMY OF NUTRITION AND DIETETICS via BGR GOVERNMENT AFFAIRS
2024 · fourth_quarter · Q4
Provide strategic counsel and advocate on issues related to health care coverage for Medical Nutritional Therapy and Intensive behavior health and other priorities for the Academy of Nutrition and Dietetics
Filing targets: Centers For Medicare and Medicaid Services (CMS), HOUSE OF REPRESENTATIVES, SENATE
CUISINE SOLUTIONS, INC. via BGR GOVERNMENT AFFAIRS
2024 · fourth_quarter · Q4
Provide strategic counsel and advocate on issues related to importing and exporting of sous vide products
Provide strategic counsel and advocate on issues related to importing and exporting of sous vide products
Filing targets: Agriculture, Dept of (USDA), SENATE
A PLACE FOR MOM, INC. via BGR GOVERNMENT AFFAIRS
2024 · fourth_quarter · Q4
Provide strategic guidance and advocacy regarding Congressional oversight of the Senior Living Referral sector.
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
BREAKTHROUGH T1D (F/K/A JDRF) via BGR GOVERNMENT AFFAIRS
2024 · fourth_quarter · Q4
Provide strategic counsel and advocate on issues related to Type 1 Diabetes policy
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
BIOMERIEUX, INC. via BGR GOVERNMENT AFFAIRS
2024 · fourth_quarter · Q4
Provide strategic counsel and advocate on issues related to diagnostic testing issues generally and bioMerieux specifically.
Filing targets: Centers For Medicare and Medicaid Services (CMS), HOUSE OF REPRESENTATIVES, SENATE
EVERYONE MEDICINES via BGR GOVERNMENT AFFAIRS
2024 · fourth_quarter · Q4
Provide strategic counsel and advocate on issues related to rare disease drug development
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
SHIFTKEY, LLC via BGR GOVERNMENT AFFAIRS
2024 · fourth_quarter · Q4
Provide strategic counsel and advocate on issues related to healthcare workforce and technology and independent contractor classification
Filing targets: Federal Trade Commission (FTC), HOUSE OF REPRESENTATIVES, SENATE
GRAIL, LLC via BGR GOVERNMENT AFFAIRS
2024 · fourth_quarter · Q4
Provide strategic counsel and advocate on issues related to oncology and multi-cancer detection, including diagnostics and screening
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
NOVARTIS via BGR GOVERNMENT AFFAIRS
2024 · fourth_quarter · Q4
Provide strategic counsel and advocacy for issues related to policies impacting the pharmaceutical industry generally including drug shortages, patient out of pocket costs, supply chain, PBM policies, kidney care policies, Inflation Reduction Act (IRA) implementation issues, the Maintaining Investments in New Innovation (MINI) Act S. 476/H.R.5547, and biopharma innovation policies.
Provide strategic counsel and advocacy for issues related to policies impacting the pharmaceutical industry generally including drug shortages, patient out of pocket costs, supply chain, PBM policies, kidney care policies, Inflation Reduction Act (IRA) implementation issues, the Maintaining Investments in New Innovation (MINI) Act S. 476/H.R.5547, and biopharma innovation policies.
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
PTC THERAPEUTICS via BGR GOVERNMENT AFFAIRS
2024 · fourth_quarter · Q4
Provide guidance and advocacy with regard to regulations and legislation that could impact the pharmaceutical industry generally, and PTC specifically.
Filing targets: Centers For Medicare and Medicaid Services (CMS), HOUSE OF REPRESENTATIVES, SENATE
BIOTECHNOLOGY INNOVATION ORGANIZATION via BGR GOVERNMENT AFFAIRS
2024 · fourth_quarter · Q4
Advise and advocate on client's behalf regarding ongoing public policy concerns impacting the innovative biotechnology industry in Congress and throughout the Administration
Filing targets: Centers For Medicare and Medicaid Services (CMS), HOUSE OF REPRESENTATIVES, SENATE
RAI SERVICES COMPANY via BGR GOVERNMENT AFFAIRS
2024 · fourth_quarter · Q4
Provide monitoring, analysis, advise and support services related to legislative and administrative policies impacting the tobacco industry
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
ADVANCED MEDICAL TECHNOLOGY ASSOCIATION via BGR GOVERNMENT AFFAIRS
2024 · fourth_quarter · Q4
Provide guidance and strategic advice regarding regulation and coverage of medical devices, including diagnostic tests
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
AMERICAN HEALTH CARE ASSOCIATION via BGR GOVERNMENT AFFAIRS
2024 · fourth_quarter · Q4
Long-term care reform; Medicare and Medicaid payment policy; Medicare Advantage policy; arbitration issues; implementation of health care reform; bad debt relief; SGR replacement; NOTICE Act; Nurse staffing shortage; appropriations
Filing targets: Centers For Medicare and Medicaid Services (CMS), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), SENATE
ALKERMES, INC. via BGR GOVERNMENT AFFAIRS
2024 · fourth_quarter · Q4
Provide strategic counsel and advocate on issues related to the biopharmaceutical industry generally, and Alkermes, Inc. specifically
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
PHARMACEUTICAL RESEARCH AND MANUFACTURERS OF AMERICA via BGR GOVERNMENT AFFAIRS
2024 · fourth_quarter · Q4
Advise and advocate on clients behalf regarding ongoing public policy concerns impacting the innovative biopharmaceutical industry in Congress and throughout the Administration.
Filing targets: Centers For Medicare and Medicaid Services (CMS), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), SENATE
APPLIED BIOLOGICS via BGR GOVERNMENT AFFAIRS
2024 · fourth_quarter · RR
Advocate on issues related to Medicare coverage
VAXCYTE, INC. via BGR GOVERNMENT AFFAIRS
2024 · fourth_quarter · RR
Provide strategic counsel and advocate on issues related to vaccine development
ALKERMES, INC. via BGR GOVERNMENT AFFAIRS
2024 · third_quarter · 3A
Provide strategic counsel and advocate on issues related to the biopharmaceutical industry generally, and Alkermes, Inc. specifically
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
ACADEMY OF NUTRITION AND DIETETICS via BGR GOVERNMENT AFFAIRS
2024 · third_quarter · Q3
Provide strategic counsel and advocate on issues related to health care coverage for Medical Nutritional Therapy and Intensive behavior health and other priorities for the Academy of Nutrition and Dietetics
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
CUISINE SOLUTIONS, INC. via BGR GOVERNMENT AFFAIRS
2024 · third_quarter · Q3
Provide strategic counsel and advocate on issues related to importing and exporting of sous vide products
Provide strategic counsel and advocate on issues related to importing and exporting of sous vide products
A PLACE FOR MOM, INC. via BGR GOVERNMENT AFFAIRS
2024 · third_quarter · Q3
Provide strategic guidance and advocacy regarding Congressional oversight of the Senior Living Referral sector.
Filing targets: SENATE
BREAKTHROUGH T1D (F/K/A JDRF) via BGR GOVERNMENT AFFAIRS
2024 · third_quarter · Q3
Provide strategic counsel and advocate on issues related to Type 1 Diabetes policy
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
BIOMERIEUX, INC. via BGR GOVERNMENT AFFAIRS
2024 · third_quarter · Q3
Provide strategic counsel and advocate on issues related to diagnostic testing issues generally and bioMerieux specifically.
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
EVERYONE MEDICINES via BGR GOVERNMENT AFFAIRS
2024 · third_quarter · Q3
Provide strategic counsel and advocate on issues related to rare disease drug development
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
SHIFTKEY, LLC via BGR GOVERNMENT AFFAIRS
2024 · third_quarter · Q3
Provide strategic counsel and advocate on issues related to healthcare workforce and technology and independent contractor classification
Filing targets: Federal Trade Commission (FTC), HOUSE OF REPRESENTATIVES, SENATE
GRAIL, LLC via BGR GOVERNMENT AFFAIRS
2024 · third_quarter · Q3
Provide strategic counsel and advocate on issues related to oncology and multi-cancer detection, including diagnostics and screening
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
NOVARTIS via BGR GOVERNMENT AFFAIRS
2024 · third_quarter · Q3
Provide strategic counsel and advocacy for issues related to policies impacting the pharmaceutical industry generally including drug shortages, patient out of pocket costs, supply chain, PBM policies, kidney care policies, Inflation Reduction Act (IRA) implementation issues, the Maintaining Investments in New Innovation (MINI) Act S. 476/H.R.5547, and biopharma innovation policies.
Provide strategic counsel and advocacy for issues related to policies impacting the pharmaceutical industry generally including drug shortages, patient out of pocket costs, supply chain, PBM policies, kidney care policies, Inflation Reduction Act (IRA) implementation issues, the Maintaining Investments in New Innovation (MINI) Act S. 476/H.R.5547, and biopharma innovation policies.
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
PTC THERAPEUTICS via BGR GOVERNMENT AFFAIRS
2024 · third_quarter · Q3
Provide guidance and advocacy with regard to regulations and legislation that could impact the pharmaceutical industry generally, and PTC specifically.
Filing targets: Centers For Medicare and Medicaid Services (CMS), HOUSE OF REPRESENTATIVES, SENATE
BIOTECHNOLOGY INNOVATION ORGANIZATION via BGR GOVERNMENT AFFAIRS
2024 · third_quarter · Q3
Advise and advocate on client's behalf regarding ongoing public policy concerns impacting the innovative biotechnology industry in Congress and throughout the Administration
Filing targets: Centers For Medicare and Medicaid Services (CMS), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), SENATE
RAI SERVICES COMPANY via BGR GOVERNMENT AFFAIRS
2024 · third_quarter · Q3
Provide monitoring, analysis, advise and support services related to legislative and administrative policies impacting the tobacco industry
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
ADVANCED MEDICAL TECHNOLOGY ASSOCIATION via BGR GOVERNMENT AFFAIRS
2024 · third_quarter · Q3
Provide guidance and strategic advice regarding FDA regulation of medical devices, including diagnostic tests
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
AMERICAN HEALTH CARE ASSOCIATION via BGR GOVERNMENT AFFAIRS
2024 · third_quarter · Q3
Long-term care reform; Medicare and Medicaid payment policy; Medicare Advantage policy; arbitration issues; implementation of health care reform; bad debt relief; SGR replacement; NOTICE Act; Nurse staffing shortage; appropriations
Filing targets: Centers For Medicare and Medicaid Services (CMS), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), SENATE
ALKERMES, INC. via BGR GOVERNMENT AFFAIRS
2024 · third_quarter · Q3
Provide strategic counsel and advocate on issues related to the biopharmaceutical industry generally, and Alkermes, Inc. specifically
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
PHARMACEUTICAL RESEARCH AND MANUFACTURERS OF AMERICA via BGR GOVERNMENT AFFAIRS
2024 · third_quarter · Q3
Advise and advocate on clients behalf regarding ongoing public policy concerns impacting the innovative biopharmaceutical industry in Congress and throughout the Administration.
Filing targets: Centers For Medicare and Medicaid Services (CMS), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), SENATE
ACADEMY OF NUTRITION AND DIETETICS via BGR GOVERNMENT AFFAIRS
2024 · third_quarter · RR
Provide strategic counsel and advocate on issues related to health care coverage for Medical Nutritional Therapy and Intensive behavior health and other priorities for the Academy of Nutrition and Dietetics
CUISINE SOLUTIONS, INC. via BGR GOVERNMENT AFFAIRS
2024 · third_quarter · RR
Provide strategic counsel and advocate on issues related to importing and exporting of sous vide products
Provide strategic counsel and advocate on issues related to importing and exporting of sous vide products
A PLACE FOR MOM, INC. via BGR GOVERNMENT AFFAIRS
2024 · second_quarter · Q2
Provide strategic guidance and advocacy regarding Congressional oversight of the Senior Living Referral sector.
BREAKTHROUGH T1D (F/K/A JDRF) via BGR GOVERNMENT AFFAIRS
2024 · second_quarter · Q2
Provide strategic counsel and advocate on issues related to Type 1 Diabetes policy
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
BIOMERIEUX, INC. via BGR GOVERNMENT AFFAIRS
2024 · second_quarter · Q2
Provide strategic counsel and advocate on issues related to diagnostic testing issues generally and bioMerieux specifically.
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
EVERYONE MEDICINES via BGR GOVERNMENT AFFAIRS
2024 · second_quarter · Q2
Provide strategic counsel and advocate on issues related to developing a Food and Drug Administration framework for single-patient products
Filing targets: Food & Drug Administration (FDA), Health & Human Services, Dept of (HHS)
SHIFTKEY, LLC via BGR GOVERNMENT AFFAIRS
2024 · second_quarter · Q2
Provide strategic counsel and advocate on issues related to healthcare workforce and technology and independent contractor classification
Filing targets: Federal Trade Commission (FTC), SENATE
GRAIL, LLC via BGR GOVERNMENT AFFAIRS
2024 · second_quarter · Q2
Provide strategic counsel and advocate on issues related to oncology and multi-cancer detection, including diagnostics and screening
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
NOVARTIS via BGR GOVERNMENT AFFAIRS
2024 · second_quarter · Q2
Provide strategic counsel and advocacy for issues related to policies impacting the pharmaceutical industry generally including drug shortages, patient out of pocket costs, supply chain, PBM policies, kidney care policies, Inflation Reduction Act (IRA) implementation issues, the Maintaining Investments in New Innovation (MINI) Act, and biopharma innovation policies.
Provide strategic counsel and advocacy for issues related to policies impacting the pharmaceutical industry generally including drug shortages, patient out of pocket costs, supply chain, PBM policies, kidney care policies, Inflation Reduction Act (IRA) implementation issues, the Maintaining Investments in New Innovation (MINI) Act, and biopharma innovation policies.
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
BIOTECHNOLOGY INNOVATION ORGANIZATION via BGR GOVERNMENT AFFAIRS
2024 · second_quarter · Q2
Advise and advocate on client's behalf regarding ongoing public policy concerns impacting the innovative biotechnology industry in Congress and throughout the Administration
Filing targets: Centers For Medicare and Medicaid Services (CMS), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), SENATE
RAI SERVICES COMPANY via BGR GOVERNMENT AFFAIRS
2024 · second_quarter · Q2
Provide monitoring, analysis, advise and support services related to legislative and administrative policies impacting the tobacco industry
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
ADVANCED MEDICAL TECHNOLOGY ASSOCIATION via BGR GOVERNMENT AFFAIRS
2024 · second_quarter · Q2
Provide guidance and strategic advice regarding FDA regulation of medical devices, including diagnostic tests
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
AMERICAN HEALTH CARE ASSOCIATION via BGR GOVERNMENT AFFAIRS
2024 · second_quarter · Q2
Long-term care reform; Medicare and Medicaid payment policy; Medicare Advantage policy; arbitration issues; implementation of health care reform; bad debt relief; SGR replacement; NOTICE Act; Nurse staffing shortage; appropriations
Filing targets: Centers For Medicare and Medicaid Services (CMS), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), SENATE
ALKERMES, INC. via BGR GOVERNMENT AFFAIRS
2024 · second_quarter · Q2
Provide strategic counsel and advocate on issues related to the biopharmaceutical industry generally, and Alkermes, Inc. specifically
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
PHARMACEUTICAL RESEARCH AND MANUFACTURERS OF AMERICA via BGR GOVERNMENT AFFAIRS
2024 · second_quarter · Q2
Advise and advocate on clients behalf regarding ongoing public policy concerns impacting the innovative biopharmaceutical industry in Congress and throughout the Administration.
Filing targets: Centers For Medicare and Medicaid Services (CMS), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), SENATE
A PLACE FOR MOM, INC. via BGR GOVERNMENT AFFAIRS
2024 · second_quarter · RA
Provide strategic guidance and advocacy regarding Congressional oversight of the Senior Living Referral sector.
A PLACE FOR MOM, INC. via BGR GOVERNMENT AFFAIRS
2024 · third_quarter · RR
Provide strategic guidance and advocacy regarding Congressional oversight of the Senior Living Referral sector.
EVERYONE MEDICINES via BGR GOVERNMENT AFFAIRS
2024 · first_quarter · Q1
Provide strategic counsel and advocate on issues related to developing a Food and Drug Administration framework for single-patient products
SHIFTKEY, LLC via BGR GOVERNMENT AFFAIRS
2024 · first_quarter · Q1
Provide strategic counsel and advocate on issues related to healthcare workforce and technology and independent contractor classification
Filing targets: Federal Trade Commission (FTC), SENATE
GRAIL, LLC via BGR GOVERNMENT AFFAIRS
2024 · first_quarter · Q1
Provide strategic counsel and advocate on issues related to oncology and multi-cancer detection, including diagnostics and screening
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
NOVARTIS via BGR GOVERNMENT AFFAIRS
2024 · first_quarter · Q1
Provide strategic counsel and advocacy for issues related to policies impacting the pharmaceutical industry generally including drug shortages, patient out of pocket costs, supply chain, PBM policies, kidney care policies, Inflation Reduction Act (IRA) implementation issues, the Maintaining Investments in New Innovation (MINI) Act, and biopharma innovation policies.
Provide strategic counsel and advocacy for issues related to policies impacting the pharmaceutical industry generally including drug shortages, patient out of pocket costs, supply chain, PBM policies, kidney care policies, Inflation Reduction Act (IRA) implementation issues, the Maintaining Investments in New Innovation (MINI) Act, and biopharma innovation policies.
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
BIOTECHNOLOGY INNOVATION ORGANIZATION via BGR GOVERNMENT AFFAIRS
2024 · first_quarter · Q1
Advise and advocate on client's behalf regarding ongoing public policy concerns impacting the innovative biotechnology industry in Congress and throughout the Administration
Filing targets: Centers For Medicare and Medicaid Services (CMS), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), SENATE
RAI SERVICES COMPANY via BGR GOVERNMENT AFFAIRS
2024 · first_quarter · Q1
Provide monitoring, analysis, advise and support services related to legislative and administrative policies impacting the tobacco industry
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
AMERICAN HEALTH CARE ASSOCIATION via BGR GOVERNMENT AFFAIRS
2024 · first_quarter · Q1
Long-term care reform; Medicare and Medicaid payment policy; Medicare Advantage policy; arbitration issues; implementation of health care reform; bad debt relief; SGR replacement; NOTICE Act; Nurse staffing shortage; appropriations
Filing targets: Centers For Medicare and Medicaid Services (CMS), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), SENATE
ALKERMES, INC. via BGR GOVERNMENT AFFAIRS
2024 · first_quarter · Q1
Provide strategic counsel and advocate on issues related to the biopharmaceutical industry generally, and Alkermes, Inc. specifically
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
PHARMACEUTICAL RESEARCH AND MANUFACTURERS OF AMERICA via BGR GOVERNMENT AFFAIRS
2024 · first_quarter · Q1
Advise and advocate on clients behalf regarding ongoing public policy concerns impacting the innovative biopharmaceutical industry in Congress and throughout the Administration.
Filing targets: Centers For Medicare and Medicaid Services (CMS), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), SENATE
BREAKTHROUGH T1D (F/K/A JDRF) via BGR GOVERNMENT AFFAIRS
2024 · second_quarter · RR
Provide strategic counsel and advocate on issues related to Type 1 Diabetes policy
EVERYONE MEDICINES via BGR GOVERNMENT AFFAIRS
2024 · first_quarter · RR
Provide strategic counsel and advocate on issues related to developing a Food and Drug Administration framework for single-patient products
ALKERMES, INC. via BGR GOVERNMENT AFFAIRS
2024 · first_quarter · RA
Provide strategic counsel and advocate on issues related to the biopharmaceutical industry generally, and Alkermes, Inc. specifically
GRAIL, LLC via BGR GOVERNMENT AFFAIRS
2023 · fourth_quarter · Q4
Provide strategic counsel and advocate on issues related to oncology and multi-cancer detection, including diagnostics and screening
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
BIOTECHNOLOGY INNOVATION ORGANIZATION via BGR GOVERNMENT AFFAIRS
2023 · fourth_quarter · Q4
Advise and advocate on client's behalf regarding ongoing public policy concerns impacting the innovative biotechnology industry in Congress and throughout the Administration
Filing targets: Centers For Medicare and Medicaid Services (CMS), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), SENATE
RAI SERVICES COMPANY via BGR GOVERNMENT AFFAIRS
2023 · fourth_quarter · Q4
Provide monitoring, analysis, advise and support services related to legislative and administrative policies impacting the tobacco industry
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
AMERICAN HEALTH CARE ASSOCIATION via BGR GOVERNMENT AFFAIRS
2023 · fourth_quarter · Q4
Long-term care reform; Medicare and Medicaid payment policy; Medicare Advantage policy; arbitration issues; implementation of health care reform; bad debt relief; SGR replacement; NOTICE Act; Nurse staffing shortage; appropriations
Filing targets: Centers For Medicare and Medicaid Services (CMS), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), SENATE
PHARMACEUTICAL RESEARCH AND MANUFACTURERS OF AMERICA via BGR GOVERNMENT AFFAIRS
2023 · fourth_quarter · Q4
Advise and advocate on clients behalf regarding ongoing public policy concerns impacting the innovative biopharmaceutical industry in Congress and throughout the Administration.
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
GRAIL, LLC via BGR GOVERNMENT AFFAIRS
2023 · fourth_quarter · RR
Provide strategic counsel and advocate on issues related to oncology and multi-cancer detection, including diagnostics and screening
SENIOR CARE PHARMACY COALITION via BGR GOVERNMENT AFFAIRS
2017 · third_quarter · 3A
Legislation and regulations affecting the long-term care pharmacy industry, S413, HR1316, HR1038
Filing targets: Food & Drug Administration (FDA), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), SENATE
PFIZER, INC via BGR GOVERNMENT AFFAIRS
2017 · fourth_quarter · 4T
Coverage and payment of new therapies
Filing targets: HOUSE OF REPRESENTATIVES, SENATE